Addkay Potassium Chloride Prolonged Release 750 mg

Description:

AddKay is a solid oral dosage form of potassium chloride and is an electrolyte replenisher. Its structural formula is KCl.

This formulation is intended to provide prolonged-release of potassium, minimise the likelihood of producing high, localised concentrations of potassium within the gastrointestinal tract. Each 750 mg of prolonged release Potassium Chloride tablet provides 10 mEq of potassium.

Composition:

Each Prolonged Release Tablet Contains Potassium Chloride I.P. 750 mg

Pharmacology:

The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function.

The normal adult plasma concentration is 3.5 to 5 mEq per litre. An active ion transport system maintains this gradient across the plasma membrane.

The usual dietary intake of potassium is 50 to 100 Eq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops slowly as a consequence of prolonged therapy with oral diuretics, primary or secondary hyperaldosteronism, diabetic ketoacidosis, severe diarrhoea, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Potassium depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis.

Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine.

If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.

Indications and Usage

1. For the therapeutic use of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.

2. For the prevention of Hypokalemia in patients who would be at particular risk if Hypokalemia were to develop, e.g., digitalised patients or patients with significant cardiac arrhythmias.

Contraindications:

Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest.

All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis) or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.

Presentation:

AddKay is available as a strip of 10 tablets & each box contains 5 such strips.